ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with Ruxolitinib

被引：1
|
作者：
Stubbs, Matthew C. [1 ]
Pusey, Michelle [1 ]
Wen, Xiaoming [1 ]
Drake, Katherine [1 ]
Zolotarjova, Nina [1 ]
Smith, Amanda [1 ]
Covington, Maryanne [1 ]
Zhang, Guofeng [1 ]
Macarron, Ricardo [2 ]
Kim, Sunkyu [1 ]
机构：
[1] Incyte Res Inst, Wilmington, DE USA
[2] Incyte, Wilmington, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181055
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
    Davis, Alison J.
    Brooijmans, Natasja
    Brubaker, Jason D.
    Stevison, Faith
    LaBranche, Timothy P.
    Albayya, Faris
    Fleming, Paul
    Hodous, Brian L.
    Kim, Joseph L.
    Kim, Sean
    Lobbardi, Riadh
    Palmer, Michael
    Sheets, Michael P.
    Vassiliadis, John
    Wang, Ruduan
    Williams, Brett D.
    Wilson, Douglas
    Xu, Lan
    Zhu, Xing Julia
    Bouchard, Keith
    Hunter, Jeffrey W.
    Graul, Chris
    Greenblatt, Elliot
    Hussein, Amira
    Lyon, Morgan
    Russo, Joelle
    Stewart, Rachel
    Dorsch, Marion
    Guzi, Timothy J.
    Kadambi, Vivek
    Lengauer, Christoph
    Garner, Andrew P.
    SCIENCE TRANSLATIONAL MEDICINE, 2024, 16 (749)
  • [32] Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma
    Ensan, Deeba
    Smil, David
    Zepeda-Velazquez, Carlos A.
    Panagopoulos, Dimitrios
    Wong, Jong Fu
    Williams, Eleanor P.
    Adamson, Roslin
    Bullock, Alex N.
    Kiyota, Taira
    Aman, Ahmed
    Roberts, Owen G.
    Edwards, Aled M.
    O'Meara, Jeff A.
    Isaac, Methvin B.
    Al-awar, Rima
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (09) : 4978 - 4996
  • [33] A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)
    Gisslinger, H.
    Skrabs, C.
    Gisslinger, B.
    Schoder, R.
    Muellauer, L.
    Kralovics, R.
    HAEMATOLOGICA, 2013, 98 : 346 - 347
  • [34] ALK2 Inhibition and a Modified Activin Receptor Type Iia Ligand Trap Cotherapy Maximized Hematologic Improvements in a Mouse Model of Anemia of Inflammation
    Wang, Chia-Yu
    Melgar-Bermudez, Emiliano
    Welch, Diana
    Tseng, Claire C.
    Fisher, Ffolliott
    Cadena, Samuel M.
    Lerner, Lorena
    Seehra, Jasbir
    Lachey, Jenn
    BLOOD, 2022, 140 : 5337 - 5338
  • [35] ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease
    Peterson, Peter
    Soh, Katherine K.
    Lee, Ye Sol
    Kim, Wontak
    Whatcott, Clifford J.
    Siddiqui-Jain, Adam
    Bearss, David J.
    Warner, Steven L.
    BLOOD, 2015, 126 (23)
  • [36] Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
    Asshoff, Malte
    Petzer, Verena
    Warr, Matthew R.
    Haschka, David
    Tymoszuk, Piotr
    Demetz, Egon
    Seifert, Markus
    Posch, Wilfried
    Nairz, Manfred
    Maciejewski, Pat
    Fowles, Peter
    Burns, Christopher J.
    Smith, Gregg
    Wagner, Kay-Uwe
    Weiss, Guenter
    Whitney, J. Andrew
    Theurl, Igor
    BLOOD, 2017, 129 (13) : 1823 - 1830
  • [37] The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib
    Al-Ali, Haifa Kathrin
    Wang, Song-Yau
    Jaekel, Nadja
    Koehler, Anne
    Krahl, Rainer
    Hubert, Karolin
    Lange, Thoralf
    Roskos, Martin
    Stengel, Rayak
    Kovacs, Ines
    Scarlett, Schwabe
    Schubert, Karoline
    Wildenberger, Kathrin
    Schneider, Melanie
    Koehler, Elisabeth
    Niederwieser, Dietger
    BLOOD, 2014, 124 (21)
  • [38] SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT
    Scherber, R.
    Dueck, A.
    Geyer, H.
    Kosiorek, H.
    Kiladjian, J. J.
    Slot, S.
    Zweegman, S.
    Boekhorst, P.
    Schouten, H.
    Sackmann, F.
    Fuentes, A.
    Hernandez-Maraver, D.
    Pahl, H.
    Stegelmann, F.
    Doehner, K.
    Bonatz, K.
    Reiter, A.
    Boyer, F.
    Etienne, G.
    Ianotto, J. C.
    Ranta, D.
    Roy, L.
    Cahn, J. Y.
    Harrison, C.
    Radia, D.
    Muxi, P.
    Maldonado, N.
    Besses, C.
    Cervantes, F.
    Johansson, P.
    Barosi, G.
    Vannucchi, A.
    Passamonti, F.
    Andreasson, B.
    Samuelsson, J.
    Birgegard, G.
    Sun, X.
    Xu, J.
    Zhang, P.
    Xu, Z.
    Barbui, T.
    Barbui, T.
    Senyak, Z.
    Grieshammer, M.
    Rambaldi, A.
    Ferrari, M.
    Lehmann, T.
    Mesa, R.
    HAEMATOLOGICA, 2016, 101 : 557 - 558
  • [39] LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA
    Belot, Audrey
    Gourbeyre, Ophelie
    Alexis, Fay
    Palin, Anais
    Besson-Fournier, Celine
    Latour, Chloe
    Hopkins, Corey R.
    Tidmarsh, George F.
    Coppin, Helene
    Roth, Marie-Paule
    Ritter, Matthew R.
    Hong, Charles C.
    Meynard, Delphine
    HAEMATOLOGICA, 2020, 105 (08) : E385 - E388
  • [40] A clinical update on BLU-782, an investigational selective ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP)
    Davis, Alison
    Albayya, Faris
    Lobbardi, Riadh
    Palmer, Michael
    Sherwin, Cori Ann
    Green, Sara
    Stevison, Faith
    Kim, Sean
    Wilkie, Gordon
    Kadambi, Vivek
    Dorsch, Marion
    Boral, Andy
    LaBranche, Timothy
    Hurtt, Mark
    Schwabb, Robert
    Stewart, Rachel
    Lyon, Morgan
    Pauplis, Rachel
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 290 - 290
12345